Home / Companies / Gilead Sciences, Inc. / 30 Apr 2026
Gilead Sciences, Inc.: meeting of 30 Apr 2026
Votes reported on Form N-PX, item by item
1,758 Form N-PX filers reported votes at the Gilead Sciences, Inc. meeting of 30 Apr 2026. Their records fall into 8 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
9 nominees; 97.0% of reported votes for; 30 filers withheld from or voted against at least one nominee.
13,093 vote records from 466 filers. 2 of the 464 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
3,164 vote records from 1,747 filers. 118 of the 1,708 filers that marked the item either way voted against management. 39 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
1,452 vote records from 464 filers. 23 of the 463 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
1,521 vote records from 475 filers. 14 of the 470 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.
DIVERSITY, EQUITY, AND INCLUSIONSecurity holder
To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation...
1,422 vote records from 454 filers. 17 of the 452 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
CORPORATE GOVERNANCESecurity holder
To vote on a stockholder proposal requesting an independent Board Chair policy
1,420 vote records from 451 filers. 101 of the 449 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
OTHER SOCIAL ISSUESSecurity holder
To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on...
1,411 vote records from 449 filers. 49 of the 446 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.
Several categoriesSecurity holder
Shareholder proposals (not separable from the filings)
Filers described these proposals in wordings that could not be matched to one another, so they are shown together.
44 vote records from 16 filers. 7 of the 15 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor | 5. Proposal | 6. Proposal | 7. Proposal |
|---|---|---|---|---|---|---|
| Vanguard | For | For | For | Against | Against | Against |
| BlackRock and iShares | For | For | For | Against | Against | Against |
| Fidelity | For | For | For | Against | Against | Against |
| Dimensional | For | For | For | Against | Against | Against |
| State Street and SPDR | For | For | For | Against | Against | Against |
| American Century | For | For | For | Against | Against | Against |
| Franklin Templeton | For | For | For | Against | Against | Against |
| Invesco | For | For | For | Against | Against | Against |
| Equitable | For | For | For | Against | Against | Against |
| Charles Schwab | For | For | For | Against | Against | Against |
| Nuveen and TIAA | For | For | For | Against | Against | Against |
| ProShares and ProFunds | For | For | For | Against | Against | Against |
| John Hancock and Manulife | For | For | For | Against | For * | Against |
| Morgan Stanley, Eaton Vance and Calvert | For | For | For | Against | Against | Against |
| J.P. Morgan | For | For | For | Against | Against | Against |
| Goldman Sachs | For | For | For | Against | Against | Against |
| WisdomTree | For | For | For | Against | Against | Against |
| PGIM and Prudential | For | For | For | Against | For * | For * |
| Jackson National funds | For | For | For | Against | Against | Against |
| Northern Trust and FlexShares | For | For | For | Against | Against | For * |
| SEI | For | For | For | Against | For * | Against |
| T. Rowe Price | For | For | For | Against | Against | Against |
| Thrivent | For | For | For | Against | Against | Against |
| Lincoln Financial | For | For | For | Against | Against | Against |
| Voya | For | For | For | Against | Against | Against |
| First Trust | For | For | For | Against | Against | Against |
| Russell Investments | For | For | For | Against | For * | Against |
| Nationwide | For | For | For | Against | Against | Against |
| Victory Capital | For | For | For | Against | Against | Against |
| Brighthouse Funds | For | For | For | Against * | Against * | Against * |
| Guggenheim and Rydex | For | For | For | Against | Against | Against |
| Columbia Threadneedle | For | For | For | Against | For * | Against |
| BNY Mellon | For | For | Against * | Against | Against | Against |
| Principal | For | For | For | Against | Against | Against |
| Capital Group and American Funds | For | For | For | Against | For * | Against |
| Pacific Life funds | For | For | For | Against | Against | Against |
| Global X | For | For | For | Against | For * | Against |
| MFS | For | Against * | For | Against | Against | Against |
| Transamerica | For | For | For | Against | Against | Against |
| Federated Hermes | For | For | For | Against | For * | Against |
| AllianceBernstein | For | For | For | Against | Against | Against |
| Hartford Funds | For | For | For | Against | Against | Against |
| DWS | For | For | For | Against | Against | For * |
| PIMCO | For | For | For | Against | Against | Against |
| Allspring | For | For | For | Against | Against | Against |
| MassMutual | For | For | For | Against | For * | Against |
| Harbor Funds | For | For | For | Against | For * | For * |
| Virtus | For | For | For | Against | Against | Against |
| VanEck | For | For | For | Against | For * | Against |
| Macquarie and Delaware Funds | For | For | For | Against | Against | Against |
| Janus Henderson | For | For | For | Against | For * | Against |
| Neuberger Berman | For | For | For | Against | For * | Against |
| American Beacon | For | For | For | Against | No report | Against |
| Natixis and Loomis Sayles | For | For | For | Against | For * | Against |
| Lord Abbett | For | For | For | Against | Against | Against |
| Dodge & Cox | For | For | For | Against | Against | Against |
| Harris Associates and Oakmark | No report | For | No report | No report | No report | No report |
| Baird | No report | For | No report | No report | No report | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Gilead Sciences, Inc. meeting?
1,758 Form N-PX filers reported votes at the meeting of 30 Apr 2026. On say-on-pay, 118 of 1,708 voted against management (6.9%). 3 proposals from security holders could be told apart in the filings. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Gilead Sciences, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Gilead Sciences, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Gilead Sciences, Inc. with a meeting date within three days of 30 Apr 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.